Valuation: PROT DIAG

Market Cap 240M 24.14M 21.23M 20.01M 18.26M 34.15M 2.32B 34.41M 93.07M 1.18B 90.62M 88.66M 3.84B P/E 2024
-2.94x
P/E 2025 -4.28x
Enterprise Value 200M 20.06M 17.64M 16.63M 15.17M 28.38M 1.93B 28.6M 77.33M 980M 75.3M 73.67M 3.19B EV / Sales 2024
2.16x
EV / Sales 2025 4.15x
Free-Float
12.26%
Yield 2024 *
-
Yield 2025 -
1 day+2.78%
1 week-4.13%
Current month+11.65%
1 month+13.94%
3 months+47.92%
6 months+3.96%
Current year+11.40%
1 week 19.4
Extreme 19.4
20.8
1 month 17.6
Extreme 17.6
23.35
Current year 12.46
Extreme 12.46
23.35
1 year 12.46
Extreme 12.46
23.35
3 years 11.7
Extreme 11.7
90.8
5 years 11.7
Extreme 11.7
169.5
10 years 11.7
Extreme 11.7
806
Manager TitleAgeSince
Chief Executive Officer 62 01/07/2020
Director of Finance/CFO 68 -
Chief Tech/Sci/R&D Officer 57 -
Director TitleAgeSince
Director/Board Member 70 01/01/2020
Director/Board Member 62 -
Director/Board Member 52 01/10/2023
Change 5-day change 1-year change 3-year change Capi.($)
+2.78%-4.13%-14.79%-74.50% 23.58M
+4.86%+6.85%+30.82%-16.55% 18.05B
-5.20%-1.26%-40.28%+23.38% 1.95B
-1.54%-0.49%-32.73%+22.85% 881M
+0.11%-0.38%+50.65%-1.91% 778M
+3.38%-3.61%-59.95%-85.08% 709M
-0.69%+8.32%-30.46%-46.60% 691M
+1.77%+5.45%-38.77%-51.24% 579M
+5.30%+4.92%+52.38%+90.73% 452M
-0.95%+0.85%-5.24%+0.85% 404M
Average +0.98%+2.44%-8.84%-13.81% 2.45B
Weighted average by Cap. +3.32%+5.26%+17.27%-12.93%

Financials

2024 2025
Net sales 36.33M 3.65M 3.21M 3.03M 2.76M 5.17M 350M 5.21M 14.08M 178M 13.71M 13.41M 580M 42.2M 4.24M 3.73M 3.52M 3.21M 6M 407M 6.05M 16.35M 207M 15.92M 15.58M 674M
Net income -26.94M -2.71M -2.38M -2.24M -2.05M -3.83M -260M -3.86M -10.44M -132M -10.16M -9.94M -430M -49.71M -5M -4.39M -4.14M -3.78M -7.07M -480M -7.12M -19.26M -244M -18.76M -18.35M -794M
Net Debt -15.73M -1.58M -1.39M -1.31M -1.2M -2.24M -152M -2.25M -6.1M -77.25M -5.94M -5.81M -251M -40.61M -4.08M -3.59M -3.38M -3.09M -5.77M -392M -5.82M -15.74M -199M -15.32M -14.99M -649M
Logo PROT DIAG
Prolight Diagnostics AB (publ) is a Sweden-based medical technology company. Together with Technology Partners, the Company develops patient-close test systems based on patented technology, for use in so-called Point of Care Testing (POCT). POCT tests are performed outside the traditional hospital laboratory, small mobile instruments enable testing near the patient and provide quick test answers. The Company focuses on the heart marker troponin.
Employees
22
Date Price Change Volume
24/09/26 SEK 19.94 +2.78% 10,873
23/09/26 SEK 19.40 -6.73% 11,919
22/09/26 SEK 20.80 +6.45% 13,338
21/09/26 SEK 19.54 +0.31% 7,227
18/09/26 SEK 19.48 -6.35% 43,075
  1. Stock Market
  2. Stocks
  3. PRLD Stock